Royalty Pharma Statistics
Total Valuation
Royalty Pharma has a market cap or net worth of $15.55 billion. The enterprise value is $21.73 billion.
Important Dates
The last earnings date was Wednesday, November 6, 2024, before market open.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | Nov 15, 2024 |
Share Statistics
Royalty Pharma has 589.18 million shares outstanding. The number of shares has increased by 33.46% in one year.
| Current Share Class | 444.30M |
| Shares Outstanding | 589.18M |
| Shares Change (YoY) | +33.46% |
| Shares Change (QoQ) | -0.70% |
| Owned by Insiders (%) | 13.55% |
| Owned by Institutions (%) | 72.53% |
| Float | 383.92M |
Valuation Ratios
The trailing PE ratio is 10.34 and the forward PE ratio is 6.33.
| PE Ratio | 10.34 |
| Forward PE | 6.33 |
| PS Ratio | 5.22 |
| Forward PS | n/a |
| PB Ratio | 1.71 |
| P/TBV Ratio | 2.27 |
| P/FCF Ratio | 5.56 |
| P/OCF Ratio | 5.56 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 18.97 |
| EV / Sales | 9.59 |
| EV / EBITDA | n/a |
| EV / EBIT | 14.07 |
| EV / FCF | 7.76 |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.74.
| Current Ratio | 1.54 |
| Quick Ratio | 1.53 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.72 |
| Interest Coverage | 7.46 |
Financial Efficiency
Return on equity (ROE) is 17.28% and return on invested capital (ROIC) is 5.75%.
| Return on Equity (ROE) | 17.28% |
| Return on Assets (ROA) | 5.69% |
| Return on Capital (ROIC) | 5.75% |
| Revenue Per Employee | $25.46M |
| Profits Per Employee | $12.87M |
| Employee Count | 89 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.97% in the last 52 weeks. The beta is 0.47, so Royalty Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -1.97% |
| 50-Day Moving Average | 27.33 |
| 200-Day Moving Average | 28.02 |
| Relative Strength Index (RSI) | 45.09 |
| Average Volume (20 Days) | 3,097,802 |
Short Selling Information
The latest short interest is 14.55 million, so 2.47% of the outstanding shares have been sold short.
| Short Interest | 14.55M |
| Short Previous Month | 14.46M |
| Short % of Shares Out | 2.47% |
| Short % of Float | 3.79% |
| Short Ratio (days to cover) | 8.05 |
Income Statement
In the last 12 months, Royalty Pharma had revenue of $2.27 billion and earned $1.15 billion in profits. Earnings per share was $2.55.
| Revenue | 2.27B |
| Gross Profit | 1.77B |
| Operating Income | 1.54B |
| Pretax Income | 673.24M |
| Net Income | 1.15B |
| EBITDA | n/a |
| EBIT | 1.54B |
| Earnings Per Share (EPS) | $2.55 |
Full Income StatementBalance Sheet
The company has $998.55 million in cash and $7.61 billion in debt, giving a net cash position of -$6.61 billion or -$11.22 per share.
| Cash & Cash Equivalents | 998.55M |
| Total Debt | 7.61B |
| Net Cash | -6.61B |
| Net Cash Per Share | -$11.22 |
| Equity (Book Value) | 10.26B |
| Book Value Per Share | 15.40 |
| Working Capital | 626.44M |
Full Balance SheetCash Flow
| Operating Cash Flow | 2.80B |
| Capital Expenditures | n/a |
| Free Cash Flow | 2.80B |
| FCF Per Share | $4.75 |
Full Cash Flow StatementMargins
Gross margin is 78.29%, with operating and profit margins of 68.13% and 50.53%.
| Gross Margin | 78.29% |
| Operating Margin | 68.13% |
| Pretax Margin | 75.64% |
| Profit Margin | 50.53% |
| EBITDA Margin | n/a |
| EBIT Margin | 68.13% |
| FCF Margin | 117.04% |
Dividends & Yields
This stock pays an annual dividend of $0.84, which amounts to a dividend yield of 3.18%.
| Dividend Per Share | $0.84 |
| Dividend Yield | 3.18% |
| Dividend Growth (YoY) | 5.00% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 32.89% |
| Buyback Yield | -33.46% |
| Shareholder Yield | -30.28% |
| Earnings Yield | 7.36% |
| FCF Yield | 18.00% |
Dividend DetailsAnalyst Forecast
The average price target for Royalty Pharma is $41.67, which is 57.84% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.67 |
| Price Target Difference | 57.84% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 5.61% |
| EPS Growth Forecast (5Y) | 22.02% |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Royalty Pharma has an Altman Z-Score of 1.63 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.63 |
| Piotroski F-Score | 5 |